Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre Goy

Showing results (101-110 of 164) with videos related to

Pageof 17
Sort By:
Leukemia & Lymphoma|January 4, 2018
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS studyPaula Cramer, Graeme Fraser, Rodrigo Santucci-Silva, et al.
British Journal of Haematology|December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer CenterDai Chihara, Chan Y Cheah, Jason R Westin, et al.
Blood|September 23, 2011
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaTodd A Fehniger, Sarah Larson, Kathryn Trinkaus, et al.
Pharmaceutical Research|May 3, 2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS TrialSilvia Maria Lavezzi, Jan de Jong, Martine Neyens, et al.
Melanoma Research|July 16, 2015
A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytesSreeja Sarojini, Andrew Pecora, Natasha Milinovikj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy, Anas Younes, Peter McLaughlin, et al.
Haematologica|July 20, 2023
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factorsSteven Le Gouill, Monika Długosz-Danecka, Simon Rule, et al.
Haematologica|September 14, 2023
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphomaTodd A Fehniger, Marcus P Watkins, Nkiruka Ezenwajiaku, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyOwen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.
Pageof 17

Showing results (101-110 of 164) with videos related to

Sort By:
Pageof 17
Leukemia & Lymphoma|January 4, 2018
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS studyPaula Cramer, Graeme Fraser, Rodrigo Santucci-Silva, et al.
British Journal of Haematology|December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer CenterDai Chihara, Chan Y Cheah, Jason R Westin, et al.
Blood|September 23, 2011
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaTodd A Fehniger, Sarah Larson, Kathryn Trinkaus, et al.
Pharmaceutical Research|May 3, 2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS TrialSilvia Maria Lavezzi, Jan de Jong, Martine Neyens, et al.
Melanoma Research|July 16, 2015
A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytesSreeja Sarojini, Andrew Pecora, Natasha Milinovikj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy, Anas Younes, Peter McLaughlin, et al.
Haematologica|July 20, 2023
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factorsSteven Le Gouill, Monika Długosz-Danecka, Simon Rule, et al.
Haematologica|September 14, 2023
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphomaTodd A Fehniger, Marcus P Watkins, Nkiruka Ezenwajiaku, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyOwen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.
Pageof 17